{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:18:38Z","timestamp":1782562718958,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11916-020-00918-z","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:47:45Z","timestamp":1613738865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Review of the Current State of Urine Drug Testing in Chronic Pain: Still Effective as a Clinical Tool and Curbing Abuse, or an Arcane Test?"],"prefix":"10.1007","volume":"25","author":[{"given":"Krishnan","family":"Chakravarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Jeha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan David","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Christo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"918_CR1","unstructured":"\u2022 Volkow N. Prescription drug abuse\u2014December 2011: a research update from the national institute on drugs abuse. Topics in Brief. 2011. This is a comprehensive research update from the National Institute on Drugs Abuse."},{"key":"918_CR2","unstructured":"Administration SAaMHS. Drug Abuse Warning Network, 2010: area profiles of drug-related mortality HHA Publication No. (SMA) 12-4699, DAWN Series D-36. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2012."},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/10550490802544938","volume":"18","author":"M Wunsch","year":"2009","unstructured":"Wunsch M, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict. 2009;18:5\u201314.","journal-title":"Am J Addict"},{"key":"918_CR4","first-page":"635","volume":"81","author":"J Standridge","year":"2010","unstructured":"Standridge J, Adams S, Zotos A. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010;81:635\u201340.","journal-title":"Am Fam Physician"},{"issue":"7","key":"918_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1526-4637.2012.01414.x","volume":"13","author":"JF Peppin","year":"2012","unstructured":"Peppin JF, Passik SD, Couto JE, Fine PG, Christo PJ, Argoff C, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886\u201396.","journal-title":"Pain Med"},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","volume":"65","author":"R Rudd","year":"2016","unstructured":"Rudd R, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015. MMWR Morb Mortal Wkly Rep. 2016;65:1445\u201352.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","volume":"10","author":"R Chou","year":"2009","unstructured":"Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113\u201330.","journal-title":"J Pain"},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1526-4637.2005.05031.x","volume":"6","author":"D Gourlay","year":"2005","unstructured":"Gourlay D, Heit H, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107\u201312.","journal-title":"Pain Med"},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","volume":"65","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep. 2016;65:1\u201349.","journal-title":"MMWR Recomm Rep"},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1526-4637.2012.01350.x","volume":"13","author":"A Pesce","year":"2012","unstructured":"Pesce A, West C, Egan City K, Strickland J. Interpretation of urine drug testing in pain patients. Pain Med. 2012;13:868\u201385.","journal-title":"Pain Med"},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3928\/01477447-20110922-22","volume":"34","author":"E Markway","year":"2011","unstructured":"Markway E, Baker S. A review of the methods, interpretation, and limitations of the urine drug screen. Orthopedics. 2011;34:877\u201381.","journal-title":"Orthopedics."},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.36076\/ppj.2017.s145","volume":"20","author":"N Knezevic","year":"2017","unstructured":"Knezevic N, Khan O, Beiranvand A, Candido K. Repeated quantitative urine toxicology analysis may improve chronic pain patient compliance with opioid therapy. Pain Physician. 2017;20:S135\u2013S45.","journal-title":"Pain Physician"},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1373\/jalm.2017.023341","volume":"2","author":"P Jannetto","year":"2018","unstructured":"Jannetto P, Bratanow N, Clark W, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline\u2013using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2:489\u2013526.","journal-title":"J Appl Lab Med"},{"key":"918_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.36076\/ppj.2011\/14\/175","volume":"14","author":"L Manchikanti","year":"2011","unstructured":"Manchikanti L, Malla Y, Wargo B, Fellows B. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC\/MS\/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. Pain Physician. 2011;14:175\u201387.","journal-title":"Pain Physician."},{"key":"918_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.36076\/ppj.2011\/14\/259","volume":"14","author":"L Manchikanti","year":"2011","unstructured":"Manchikanti L, Malla Y, Wargo B, Fellows B. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC\/MS\/MS) of urine drug testing. Pain Physician. 2011;14:259\u201370.","journal-title":"Pain Physician."},{"key":"918_CR16","first-page":"53","volume":"11","author":"K Kirsch","year":"2015","unstructured":"Kirsch K, Christo P, Heit H, Steffel K, Passik S. Specimen validity testing in urine drug monitoring of medications and illicit drugs: clinical implications. J Opioid Manag. 2015;11:53\u20139.","journal-title":"J Opioid Manag."},{"key":"918_CR17","doi-asserted-by":"crossref","unstructured":"Lynch K. Specimen validity testing: is it \u201cvalid\u201d for drug testing in pain management?, J Appl Lab Med. 2018;2:478\u201380.","DOI":"10.1373\/jalm.2017.023168"},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addbeh.2017.01.011","volume":"69","author":"MM Ali","year":"2017","unstructured":"\u2022\u2022 Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey of Drug Use and Health. Addict Behav. 2017;69:65\u201377 This paper discusses evidence from the National Survey of Druge Use and Health regarding prescription drug monitoring programs.","journal-title":"Addict Behav"},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1377\/hlthaff.2015.1673","volume":"35","author":"Y Bao","year":"2016","unstructured":"Bao Y, Pan Y, Taylor A, Radakrishnan S, Lu F, Pincus H, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35:1045\u201351.","journal-title":"Health Aff (Millwood)"},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","volume":"35","author":"S Patrick","year":"2016","unstructured":"Patrick S, Fry C, Jones T, Buntin M. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35:1324\u201332.","journal-title":"Health Aff (Millwood)"},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.36076\/ppj.2010\/13\/401","volume":"13","author":"L Manchikanti","year":"2010","unstructured":"Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a tenyear perspective. Pain Physician. 2010;13:401\u201335.","journal-title":"Pain Physician"},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"T Kosten","year":"2002","unstructured":"Kosten T, George T. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1:13\u201320.","journal-title":"Sci Pract Perspect"},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00023210-200418010-00002","volume":"18","author":"S Passik","year":"2004","unstructured":"Passik S, Kirsch K. Opioid therapy in patients with a history of substance abuse. CNS Drug. 2004;18:13\u201325.","journal-title":"CNS Drug"},{"key":"918_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11916-004-0010-3","volume":"8","author":"S Passik","year":"2004","unstructured":"Passik S, Kirsch K. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Rep. 2004;8:289\u201394.","journal-title":"Curr Pain Headache Rep"},{"key":"918_CR25","first-page":"249","volume":"297","author":"B Kuehn","year":"2007","unstructured":"Kuehn B. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297:249\u201351.","journal-title":"JAMA."},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2017.01.008","volume":"46","author":"GA Victor","year":"2017","unstructured":"Victor GA, Walker R, Cole J, Logan TK. Opioid analgesics and heroin: examining drug misuse trends among a sample of drug treatment clients in Kentucky. Int J Drug Policy. 2017;46:1\u20136.","journal-title":"Int J Drug Policy"},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugpo.2017.05.001","volume":"46","author":"JA Ford","year":"2017","unstructured":"Ford JA, Sacra SA, Yohros A. Neighborhood characteristics and prescription drug misuse among adolescents: the importance of social disorganization and social capital. Int J Drug Policy. 2017;46:47\u201353.","journal-title":"Int J Drug Policy"},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","volume":"30","author":"M Serdarevic","year":"2017","unstructured":"Serdarevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017;30:238\u201346.","journal-title":"Curr Opin Psychiatry"},{"key":"918_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugalcdep.2017.02.027","volume":"176","author":"A Roxburgh","year":"2017","unstructured":"Roxburgh A, Darke S, Salmon AM, Dobbins T, Jauncey M. Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. Drug Alcohol Depend. 2017;176:126\u201332.","journal-title":"Drug Alcohol Depend"},{"key":"918_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-016-0068-3","volume":"12","author":"T Kerensky","year":"2017","unstructured":"Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don\u2019t know. Addict Sci Clin Pract. 2017;12:4.","journal-title":"Addict Sci Clin Pract"},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugpo.2017.05.012","volume":"45","author":"\u00c9 Roy","year":"2017","unstructured":"Roy \u00c9, Arruda N, Leclerc P, Morissette C, Blanchette C, Blouin K, et al. Drug use practices among people who inject drugs in a context of drug market changes: challenges for optimal coverage of harm reduction programs. Int J Drug Policy. 2017;45:18\u201324.","journal-title":"Int J Drug Policy"},{"key":"918_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? J Subst Abus Treat. 2017;78:1\u20137.","journal-title":"J Subst Abus Treat"},{"key":"918_CR33","first-page":"00","volume":"52","author":"A Estreet","year":"2017","unstructured":"Estreet A, Archibalde P, Tirmazi MT, Goodman S, Cujoe T. Exploring social work student education: the effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders. Subst Abus. 2017;52:00.","journal-title":"Subst Abus"},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drugpo.2017.03.003","volume":"44","author":"JL Syvertsen","year":"2017","unstructured":"Syvertsen JL, Paquette CE, Pollini RA. Down in the valley: trajectories of injection initiation among young injectors in California\u2019s Central Valley. Int J Drug Policy. 2017;44:41\u20139.","journal-title":"Int J Drug Policy"},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40732-017-0235-2","volume":"67","author":"LZ Meshesha","year":"2017","unstructured":"Meshesha LZ, Pickover AM, Teeters JB, Murphy JG. A longitudinal behavioral economic analysis of non-medical prescription opioid use among college students. Psychol Rec. 2017;67:241\u201351.","journal-title":"Psychol Rec"},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.annemergmed.2017.02.007","volume":"69","author":"S Bellew","year":"2017","unstructured":"Bellew S, Barrett TW. Loperamide will stop you up but it can also bring you down. Ann Emerg Med. 2017;69:786\u201391.","journal-title":"Ann Emerg Med"},{"key":"918_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","volume":"374","author":"W Compton","year":"2016","unstructured":"Compton W, Jones C, Baldwin G. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154\u201363.","journal-title":"N Engl J Med"},{"key":"918_CR38","first-page":"S30S92","volume":"20","author":"L Manchikanti","year":"2017","unstructured":"Manchikanti L, Kaye A, Knezevic N, McAnally H, Slavin K, Trescot A, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20:S30S92.","journal-title":"Pain Physician"},{"key":"918_CR39","doi-asserted-by":"crossref","unstructured":"Gourlay D, Heit H. Pain and addiction: managing risk through comprehensive care. J Addict Dis. 27:23\u201330.","DOI":"10.1080\/10550880802122570"},{"key":"918_CR40","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.36076\/ppj.2010\/13\/E1","volume":"13","author":"L Manchikanti","year":"2010","unstructured":"Manchikanti L, Malla Y, Wargo B, Cash K, Pampati V, Damron K, et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC\/MS\/MS). Pain Physician. 2010;13:E1\u2013E22.","journal-title":"Pain Physician."},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.36076\/ppj.2017.s145","volume":"20","author":"N Knezevic","year":"2017","unstructured":"\u2022\u2022 Knezevic N, Khan O, Beiranvand A, Candido K. Repeated quantitative urine toxicology analysis may improve chronic pain patient compliance with opioid Therapy. Pain Physician. 2017;20:S135\u2013S45 This analysis suggests that repeated quantitative urine toxicology analysis may improve compliance in patients using chronic opioids.","journal-title":"Pain Physician"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5055\/jom.2014.0200","volume":"10","author":"YD Yee","year":"2014","unstructured":"Yee YD, Hughes M, Guo A, Barakat N, Tse S, Ma J, et al. Observation of improved adherence with frequent urine drug testing in patients with pain. J Opioid Manag. 2014;10:111\u20138.","journal-title":"J Opioid Manag"},{"key":"918_CR43","first-page":"45","volume":"11","author":"B Morasco","year":"2015","unstructured":"Morasco B, Krebs E, Cavanagh R, Hyde S, Crain A, Dobscha S. Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy. J Opioid Manag. 2015;11:45\u201351.","journal-title":"J Opioid Manag."},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.36076\/ppj.2011\/14\/123","volume":"14","author":"P Christo","year":"2011","unstructured":"Christo P, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki D, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123\u201343.","journal-title":"Pain Physician."},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jpain.2007.11.014","volume":"9","author":"S Butler","year":"2008","unstructured":"Butler S, Fernandez K, Benoit C, Budman S, Jamison R. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9:360\u201372.","journal-title":"J Pain"},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.pain.2007.01.014","volume":"130","author":"S Butler","year":"2007","unstructured":"Butler S, Budman S, Fernandez K, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130:144\u201356.","journal-title":"Pain."},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/j.1526-4637.2009.00743.x","volume":"10","author":"T Moore","year":"2009","unstructured":"Moore T, Jones T, Browder J, Daffron S, Passik S. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10:1426\u201333.","journal-title":"Pain Med"},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/pme.12221","volume":"14","author":"R Hamill-Ruth","year":"2013","unstructured":"Hamill-Ruth R, Larriviere K, McMasters M. Addition of objective data to identify risk for medication misuse and abuse: the inconsistency score. Pain Med. 2013;14:1900\u20137.","journal-title":"Pain Med"},{"key":"918_CR49","doi-asserted-by":"publisher","unstructured":"\u2022 Ko M, Woster P, Smith T. (205) Predictors of illicit substance use assessed by urine drug monitoring in patients prescribed opioid medications. The Journal of Pain (2016);17(4):S27. https:\/\/doi.org\/10.1016\/j.jpain.2016.01.108. This review is an excellent manuscript on profiles of drug-related mortality.","DOI":"10.1016\/j.jpain.2016.01.108"},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jpain.2016.01.110","volume":"17","author":"P Woster","year":"2016","unstructured":"Woster P, Ko M, Smith T. Predictors of medication adherence assessed by urine drug monitoring in patients prescribed opioid medications: relationship with opioid dose. J Pain. 2016;17:S27.","journal-title":"J Pain"},{"key":"918_CR51","doi-asserted-by":"crossref","unstructured":"Morasco B, Peters D, Krebs E, Kovas A, Hart K, Dobscha S. Predictors of urine drug testing for patients with chronic pain: results from a national cohort of U.S. veterans. Subst Abus. 37:82\u20137.","DOI":"10.1080\/08897077.2015.1110742"},{"key":"918_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.36076\/ppj.2006\/9\/57","volume":"9","author":"R Manchikanti","year":"2006","unstructured":"Manchikanti R, Manchikanti L, Damron K, Brandon D, McManus C, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9:57\u201360.","journal-title":"Pain Physician."},{"key":"918_CR53","first-page":"S67","volume":"15","author":"L Manchikanti","year":"2012","unstructured":"Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2\u2013guidance. Pain Physician. 2012;15:S67\u2013S116.","journal-title":"Pain Physician"},{"key":"918_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/AJP.0b013e31817e13cc","volume":"25","author":"A Nafzinger","year":"2009","unstructured":"Nafzinger A, Bertino J. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25:73\u20139.","journal-title":"Clin J Pain"},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5055\/jom.2007.0044","volume":"3","author":"G Reisfield","year":"2007","unstructured":"Reisfield G, Bertholf R, Barking R, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007;3:80\u20136.","journal-title":"J Opioid Manag"},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"420","DOI":"10.7326\/0003-4819-153-6-201009210-00018","volume":"153","author":"G Reisfield","year":"2010","unstructured":"Reisfield G, Graham N, Gold M. Urine drug testing is still an invaluable resource for primary care. Ann Intern Med. 2010;153:420 author reply -1.","journal-title":"Ann Intern Med"},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4065\/83.1.66","volume":"83","author":"K Moeller","year":"2008","unstructured":"Moeller K, Lee K, Kissack J. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83:66\u201376.","journal-title":"Mayo Clin Proc"},{"key":"918_CR58","first-page":"301","volume":"37","author":"G Reisfield","year":"2007","unstructured":"Reisfield G, Salazar E, Bertholf R. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37:301\u201314.","journal-title":"Ann Clin Lab Sci"},{"key":"918_CR59","first-page":"47","volume":"10","author":"AH Wu","year":"1998","unstructured":"Wu AH. Integrity of urine specimens submitted for toxicologic analysis: adulteration, mechanisms of action, and laboratory detection. Forensic Sci Rev. 1998;10:47\u201365.","journal-title":"Forensic Sci Rev"},{"issue":"5321","key":"918_CR60","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","volume":"276","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276(5321):2048\u201350.","journal-title":"Science."},{"issue":"3","key":"918_CR61","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1523\/JNEUROSCI.21-03-00823.2001","volume":"21","author":"JJ Rodriguez","year":"2001","unstructured":"Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci. 2001;21(3):823\u201333.","journal-title":"J Neurosci"},{"issue":"6","key":"918_CR62","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jpain.2016.02.007","volume":"17","author":"SR Savage","year":"2016","unstructured":"Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, et al. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17(6):654\u201368.","journal-title":"J Pain"},{"issue":"3","key":"918_CR63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jpainsymman.2003.07.008","volume":"27","author":"HA Heit","year":"2004","unstructured":"Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manag. 2004;27(3):260\u20137.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"918_CR64","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.36076\/ppj.2010\/13\/E1","volume":"13","author":"L Manchikanti","year":"2010","unstructured":"Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC\/MS\/MS). Pain Physician. 2010;13(1):E1\u2013e22.","journal-title":"Pain Physician."},{"issue":"3","key":"918_CR65","first-page":"155","volume":"35","author":"A St John","year":"2014","unstructured":"St John A, Price CP. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev. 2014;35(3):155\u201367.","journal-title":"Clin Biochem Rev"},{"issue":"4","key":"918_CR66","first-page":"38","volume":"35","author":"M Raouf","year":"2018","unstructured":"Raouf M, Bettinger JJ, Fudin J. A practical guide to urine drug monitoring. Fed Pract. 2018;35(4):38\u201344.","journal-title":"Fed Pract"},{"issue":"2","key":"918_CR67","first-page":"154","volume":"25","author":"HN James","year":"2014","unstructured":"James HN. Risk management for point-of-care testing. Ejifcc. 2014;25(2):154\u201361.","journal-title":"Ejifcc."},{"issue":"3","key":"918_CR68","first-page":"147","volume":"27","author":"OH Drummer","year":"2006","unstructured":"Drummer OH. Drug testing in oral fluid. Clin Biochem Rev. 2006;27(3):147\u201359.","journal-title":"Clin Biochem Rev"},{"issue":"11","key":"918_CR69","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1373\/clinchem.2008.108670","volume":"55","author":"WM Bosker","year":"2009","unstructured":"Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009;55(11):1910\u201331.","journal-title":"Clin Chem"},{"issue":"2\u20133","key":"918_CR70","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.drugalcdep.2006.08.020","volume":"87","author":"R Dams","year":"2007","unstructured":"Dams R, Choo RE, Lambert WE, Jones H, Huestis MA. Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend. 2007;87(2\u20133):258\u201367.","journal-title":"Drug Alcohol Depend"},{"key":"918_CR71","volume-title":"Validity self-reported drug use Improv Accuracy Surv Estim","author":"EJ Cone","year":"1997","unstructured":"Cone EJ. New developments in biological measures of drug prevalence. In: Harrison L, Hughes A, editors. Validity self-reported drug use Improv Accuracy Surv Estim. Bethesda: National Institute on Drug Abuse; 1997."},{"issue":"2","key":"918_CR72","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/00007691-200404000-00020","volume":"26","author":"AG Verstraete","year":"2004","unstructured":"Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26(2):200\u20135.","journal-title":"Ther Drug Monit"},{"issue":"2\u20133","key":"918_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.forsciint.2005.02.028","volume":"150","author":"DJ Crouch","year":"2005","unstructured":"Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005;150(2\u20133):165\u201373.","journal-title":"Forensic Sci Int"},{"key":"918_CR74","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/FPC.0b013e32832b89da","volume":"19","author":"J Lotsch","year":"2009","unstructured":"Lotsch J, von Hentig N, Freynhagen R. Cross sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009;19:429\u201336.","journal-title":"Pharmacogenet Genomics"},{"key":"918_CR75","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jat\/bks019","volume":"36","author":"N Barakat","year":"2012","unstructured":"Barakat N, Atayee R, Best B. Relationship between the concentration of hydrocodone and its converstion to hydromorphone in chronic pain patients using urinary excretion data. J Anal Toxicol. 2012;36:257\u201364.","journal-title":"J Anal Toxicol"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-020-00918-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-020-00918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:48:41Z","timestamp":1666756121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-020-00918-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s11916-020-00918-z","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"21 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interest as relates to this body of work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"12"}}